Roivant Sciences Ltd. (NASDAQ:ROIV) Brepocitinib in DM: VALOR Phase 3 Study Results Conference September 17, 2025 08:00 AM EDT
Company Participants
Stephanie Lee Griffin – Chief Operating Officer of Roivant Platforms
Matthew Gline – CEO & Director
Benjamin Zimmer – CEO, Priovant
Conference Call Participants
Yuchen Ding – Jefferies LLC, Research Division
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Yaron Werber – TD Cowen, Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Samuel Slutsky – LifeSci Capital, LLC, Research Division
Samantha Semenkow – Citigroup Inc., Research Division
Yatin Suneja – Guggenheim Securities, LLC, Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Ladies and gentlemen, thank you for standing by. Welcome to VALOR Phase III study results [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the conference over to Stephanie Lee. Please go ahead.
Stephanie Lee Griffin
Chief Operating Officer of Roivant Platforms
Good morning, and thanks for joining today’s call to review the VALOR Phase III study results. I’m Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant; and Ben Zimmer, CEO of Priovant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com.
We’ll also be providing the current slide numbers as we present to help you follow along. I’d like to remind you that we’ll be making certain forward-looking statements during today’s presentation. We strongly encourage you to review the information that we filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties. And with that, I’ll turn it over to Matt.
Matthew Gline
CEO & Director
Read the full article here
